Journal
NATURE REVIEWS IMMUNOLOGY
Volume 10, Issue 7, Pages 527-535Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nri2801
Keywords
-
Categories
Funding
- Bill and Melinda Gates Foundation
- US National Institutes of Health [HL59725, AI38065, DP2 OD004631, AI084119]
- US Department of Veterans Affairs
Ask authors/readers for more resources
One of the main challenges of developing an HIV-1 vaccine lies in eliciting immune responses that can overcome the antigenic variability exhibited by HIV. Most HIV-1 vaccine development has focused on inducing immunity to conserved regions of the HIV-1 envelope. However, new studies of the sequence-variable regions of the HIV-1 gp120 envelope glycoprotein have shown that there are conserved immunological and structural features in these regions. Recombinant immunogens that include these features may provide the means to address the antigenic diversity of HIV-1 and induce protective antibodies that can prevent infection with HIV-1.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available